In August 2002, LG Life Sciences was upgraded from a business division to a full-fledged LG affiliate to grow as a life sciences specialist and maximize shareholder value.

LG Life Sciences began research in genetic engineering in 1981 and has invested steadily in the life sciences ever since. This effort has already resulted in world-class technology and product capabilities. The company has focused research and development resources on three areas—pharmaceuticals, animal health, and specialty chemicals.

LG Life Sciences has developed and commercialized an array of pharmaceuticals including interferon in 1989 (Intermax-gamma) and 1992 (Intermax-alpha), the hepatitis B vaccine in 1992 (EUVAX B), the human growth hormone in 1993 (EUTROPIN?), a degenerative arthritis treatment in 2005 (HYRUAN Plus?), rhFSH (recombinant human follicle stimulating hormone) in 2006 (Follitrope?), and SR-hGH (sustained release human growth hormone) in 2007 (Declage?). A company milestone was reached in 2003 when its next-generation quinolone antibiotic (FACTIVE??) was approved by the U.S. Food and Drug Administration.

LG Life Sciences has succeeded in animal health products including the 1994 commercialization of recombinant bovine somatotropin (BOOSTIN??). The product, which is used to increase milk production in lactating dairy cows, has achieved the top share in numerous national markets. In 2006, the company launched a bovine mastitis vaccine (MastaVac) that reduces the number of somatic cells, relieving clinical symptoms in cows infected with mastitis.

In the area of specialty chemicals, LG Life Sciences completed in-house development of Korea's first new herbicide (PYANCOR??) for rice in 1997 and fungicide (GUARDIAN??) for use in horticulture in 1999. A new herbicide (FLUXO??) for both pre- and post-emergent rice was completed in 2004.

LG Life Sciences has a vision to become a top-tier life sciences company with world-class new drugs. The company is expanding its strategic alliances and fostering its capabilities to identify candidate drugs for development. The company's development of new medicines is accelerating and marketing competencies are being focused on advanced markets.

In the future, LG Life Sciences will remain a leader in life sciences and biotechnology areas that are knowledge intensive.

- An array of pharmaceuticals and genetic engineering products, including growth hormone drugs, hypertension drugs, arthritis drugs, infertility drugs, anti-cancer drugs, psychiatric drugs, renal anemia drugs, urology drugs, eye operation aiding drugs, interferon, dietary supplements, and diagnostic reagents.
- Animal drugs including bovine somatotropin (BST).
- Agrochemicals including pesticides, disinfectants, and herbicides.